Skip to main content

Ipsen provides update on legacy of Henri Beaufour

PARIS, FRANCE, 5 December 2025, Ipsen (Euronext: IPN; ADR: IPSEY) has been informed that the shares of Beech Tree will be transferred to the Alasol Foundation, in accordance with the wishes of Mr. Henri Beaufour, Ipsen’s Board Member and a representative of the founding family who passed away on November 28, 2025. This transfer is expected to take place in early 2026 after having obtained the required regulatory approvals*. Beech Tree is the holding company owning directly and indirectly the stake in Ipsen shares of Mr. Beaufour. Alasol Foundation is a public interest foundation created by Mr. Beaufour to promote education, school and vocational training for disadvantaged children and young adults. This transfer of shares has no effect on the existing shareholders’ agreement between Beech Tree and Highrock. About Ipsen We are a...

Continue reading

ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025

Highly differentiated 1L EGFR PACC preliminary systemic activity of 80% ORR and 100% intracranial ORR, including in patients with active brain metastases 36% ORR in median 3L EGFR PACC patients exceeds competitor benchmarks Competitive safety profile, with no significant off-target toxicity and manageable on-target toxicity, resulting in low discontinuation rate Enrollment and follow-up continue in 1L EGFR PACC patients at selected dose of 80 mg once daily, with next update expected mid-2026 ahead of initiation of potential Phase 3 trial Company to host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ET SOUTH SAN FRANCISCO and SAN DIEGO, Dec. 04, 2025 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of...

Continue reading

Transcenta Therapeutics Presents Updated Efficacy Data from the Phase I/II Transtar102 Trial of Osemitamab plus Nivolumab and CAPOX in First-Line G/GEJ Cancer at ESMO Asia

Data showed encouraging results in patients with higher CLDN18.2 expression regardless of PD-L1 expression level, with a median PFS of 16.6 months, ORR of 68% and median DoR of 18 months PRINCETON, N.J. and SUZHOU, China, Dec. 04, 2025 (GLOBE NEWSWIRE) — Transcenta Holding Limited (HKEX: 06628) (“Transcenta Therapeutics”), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, today announced updated efficacy analysis of Cohort G by CLDN18.2 and PD-L1 expression from the phase I/II Transtar102 trial of osemitamab plus nivolumab and CAPOX in first-line Gastric/Gastroesophageal Junction (G/GEJ) cancer. The new findings were showcased in a poster presentation (Abstract #299P) at the ESMO Asia Congress 2025...

Continue reading

CEA Industries (Nasdaq: BNC) Responds to YZi Labs, Re-Affirms Commitment to BNB DAT Strategy, and Welcomes Shareholder Engagement

Shareholders do not need to take any action at this time Louisville, CO, Dec. 04, 2025 (GLOBE NEWSWIRE) — CEA Industries Inc. (Nasdaq: BNC) (“BNC” or the “Company”), which manages the world’s largest corporate treasury of BNB, today issued the following statement regarding its commitment to the BNB token, and its ongoing work to strengthen its Board of Directors and sharpen its operations. The Company acknowledges recent shareholder communications by YZILabs Management Ltd. (“YZi”), including most recently a press release issued on December 3, 2025. Contrary to the statements in that press release, the Company remains committed to becoming the world’s largest BNB treasury company. Since the July PIPE investment, BNC has never considered an alternative token for the Company’s digital asset treasury (“DAT”) strategy, nor launched...

Continue reading

Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA

ROCKVILLE, Md. and SUZHOU, China, Dec. 04, 2025 (GLOBE NEWSWIRE) — Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it has received clearance from the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to conduct a global registrational Phase III study (POLARIS-1; NCT06051409) of its compound under investigation, olverembatinib, in combination with chemotherapy for the treatment of newly diagnosed patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). As the second global registrational Phase III study of olverembatinib that has been cleared...

Continue reading

FormFactor Announces Participation in 14th Annual NYC Summit

LIVERMORE, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) — FormFactor, Inc. (Nasdaq: FORM) today announced that it will be joining 14 other companies in collectively hosting the 14th Annual NYC Summit investor conference, being held Tuesday, December 16th at Mastro’s Steakhouse New York. The presentation material utilized during the NYC Summit will be made accessible on the events page of the Company’s website at www.formfactor.com. About the 14th Annual NYC SummitThe NYC Summit is collectively hosted and funded by participating companies and features a “round-robin” format consisting of small group meetings with company management teams. During the event, investors and analysts will have the opportunity to meet with the majority of the 15 management teams during the small group meeting sessions, as well as opportunities to meet with...

Continue reading

Miata Metals Announces Filing of Final Short Form Prospectus – Accessible on SEDAR+

Not for distribution to United States newswire services or for dissemination in the United States VANCOUVER, British Columbia, Dec. 04, 2025 (GLOBE NEWSWIRE) — Miata Metals Corp. (CSE:MMET) (FSE: 8NQ) (OTCQB: MMETF) (“Miata” or the “Company”) is pleased to announce that, further to its news release dated November 18, 2025, it has filed a final short form prospectus dated December 3, 2025 (the “Final Prospectus”) with the securities commissions in each of the provinces of Canada, except Quebec, in connection with its public offering of common shares of the Company (the “Common Shares”) at $0.48 per Common Share for aggregate gross proceeds of up to $10,000,080 (the “Offering”). The Offering is being conducted through a syndicate of agents led by Cormark Securities Inc. (collectively, the “Agents”). The Company has granted the Agents...

Continue reading

North American Niobium and Critical Minerals Corp. Announces Private Placement of Flow-Through Shares

– NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES – Vancouver, BC, Dec. 04, 2025 (GLOBE NEWSWIRE) — North America Niobium and Critical Minerals Corp. (CSE: NIOB) (FSE: IOR) (OTCQB: NIOMF) (“North American Niobium” or the “Company”) is pleased to announce that it will proceed with a non-brokered private placement of up to 689,655 flow-through common shares in the capital of the Company (the “FT Shares”) at $1.45 per FT Share for gross proceeds of up to $1,000,000 (the “Offering”). Each FT Share will be issued as a “flow-through share” as defined in subsection 66(15) of the Income Tax Act (Canada) and in section 359.1 of the Taxation Act (Quebec) with respect to purchasers in Quebec. In connection with the Offering, the Company will pay finders’ fees of up to 7.0% of the gross proceeds raised...

Continue reading

authID Selected to Biometrically Secure Identities for Online Educational Services at Correctional Facilities

Fastest-growing educational technology leader replaces homegrown solution with authID to enable authentication, protect privacy, and prevent fraud for distance learning in complex environments DENVER, CO, Dec. 04, 2025 (GLOBE NEWSWIRE) — authID (Nasdaq: AUID), a leader in biometric identity authentication, today announced it was selected by an east coast-based innovative technology organization, serving the criminal justice sector, providing high quality education, reentry and rehabilitation resources for both adult and juvenile incarcerated individuals, to provide biometric identity proofing and authentication through its platform for administrators, staff, support teams, and justice-impacted constituents. authID was chosen to replace the organization’s existing homegrown biometric authentication solution, after they conducted...

Continue reading

Costco Wholesale Corporation Announces Nomination of Gina Raimondo to Board of Directors

ISSAQUAH, Wash., Dec. 04, 2025 (GLOBE NEWSWIRE) — Costco Wholesale Corporation (“Costco” or the “Company”) (Nasdaq: COST) today announced the nomination for election to its Board of Directors of Secretary Gina Raimondo. Raimondo was the 40th Secretary of Commerce, from 2021 to 2025, and Governor of Rhode Island from 2015 to 2021. She entered politics in 2010, when she was elected Treasurer of the State of Rhode Island. Prior to entering politics Secretary Raimondo worked in venture capital. She is also a distinguished fellow at the Council on Foreign Relations. Hamilton (Tony) James, Chairman of the Board, stated: “We are very pleased to nominate Secretary Raimondo for election to our Board. Her vast experience in global business, politics and international security at the highest level will add an important dimension to our current...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.